Nottingham based contract research organisation (CRO) Cellomatics Biosciences has expanded its team with the appointment of senior molecular biologist, Dr Lara De Tomasi, in response to recent growth and the continued increase in demand for its bespoke preclinical and early discovery phase expertise.
A specialist in genetics and molecular biology, Lara joins Cellomatics from the University of Sheffield where she was a Research Associate in the Mirna Mustapha Lab, working on the genetics and molecular heterogeneity of spiral ganglion neurons. Prior to this, Lara spent three years at the…
London, UK, 10 February 2022: PharmaVentures today announced it has moved its operational headquarters from Oxford to London as part of its continued strategic expansion. The company will retain its remaining operational and administrative functions at its new registered office in Oxford. Dr Fintan Walton, Chief Executive and Founder of PharmaVentures said: “As a leading global transaction advisory firm, it makes sense that PharmaVentures moves its functional operations to one of world’s leading financial cities. We wanted a location that reflects PharmaVentures’ forward-thinking culture…
Cambridge, United Kingdom, 10th February 2022 / Sciad Newswire / Domainex Ltd., a leading integrated medicines research services partner, today announces it has opened a facility of over 7,000 sq ft at Unity Campus in Sawston – Cambridge’s newest science and technology park encompassing Iconix Park and The Works, and owned by leading regional property and investment firm Howard Group.
The Domainex facility has fully equipped and operational laboratories and consolidates the Company’s footprint in the Cambridge bioscience cluster. Following two years of very strong growth for the business,…
The UK Government’s recently released “Levelling up White Paper” makes for interesting reading in the context of the life sciences sector.
In advance of a more in-depth review, here are some of the key points and my thoughts, focusing on two of the main areas of relevance to the sector: small company finance and R&D expenditure.
The White Paper does a good job of setting out the challenges. For example, it identifies that 86% of equity investment in the UK goes to companies in London, the South East and East of England. Data shown in the forthcoming UK Life Science Start-up Report states…
Cambridge UK: 07 February 2022
Bidwells LLP, widely recognized as a pioneer and the leading science & technology property adviser in the UK has become the latest Partner to join One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs of the Partner and One Nucleus members.
Max Bryan, Head of Science & Technology commented “Bidwells is committed to ensuring the rapidly growing science and technology sector in the Oxford – Cambridge Arc is fully catered for when it comes to its R&D and office requirements. We are already advising on 31 science parks and…
London & Cambridge, United Kingdom, 3rd February 2022 / Sciad Newswire / Parkinson’s UK, the largest charitable funder of Parkinson’s research in Europe, and Domainex Ltd., today announce a collaboration focused on developing small molecule therapies targeting neuroinflammation that could slow the progression of Parkinson’s. Domainex, a leading integrated medicines research services partner, will provide fully integrated drug discovery services including assay biology, medicinal and computational chemistry. The collaboration is anticipated to be undertaken over a two-and-a-half-year…
CAMBRIDGE, UK (02 Feb 2022) – Nuclera, a biotech company developing cutting-edge benchtop protein printing technologies, today announced that the first close of its Series B financing has raised $42.5 million. The funds raised will be used to accelerate the development and commercialization of its eProtein™ desktop bioprinter.
Nuclera’s ground-breaking protein printing technology has attracted many new and existing institutional and strategic investors in this financing round including M&G, Amadeus Capital Partners, E Ink, RT Partners, Future Planet Capital, British Business Bank Future…
Cambridge, UK, February 1, 2022 — Biofidelity, a pioneer in precision cancer diagnostics, has successfully completed a heavily oversubscribed $23 million Series A+ investment round, led by Octopus Ventures and backed by SBI Investment Co. Ltd. and existing investors. The investment will fund the upcoming launch of ASPYRE-Lung, the company’s first commercial diagnostic assay based on its breakthrough molecular technology.
ASPYRE is a completely new category of molecular diagnostic technology that simplifies and accelerates the detection of genomic biomarkers. The technology has been developed…
OXFORD, UK January 31, 2022 –PrecisionLife Limited, the global techbio company driving precision medicine in chronic disease with AI-led drug discovery, clinical development, and healthcare solutions, announces the first close of its Series A investment round. The financing, which is ongoing, will enable expansion and progression of its extensive and growing pipeline of commercial opportunities targeting complex chronic diseases. The company anticipates the second close of the Series A investment round in the coming months.
The investment will be used to expand the application of…